DT&CRO CO., Ltd.
Financials
Valuation Metrics
DT&CRO CO., Ltd.'s Market Cap is ₩213B. At end of 2025 it was ₩331B. Ranked #2300 of 2,421 in KR market (top 95%), #1532 of 1,640 on KOSDAQ (top 93%), #225 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 21.32B KRW | KR#2,300/2,421 Sec#225/231 |
| Revenue | 49.00B KRW | KR#1,805/2,421 Sec#124/231 |
| Net Income | -17.09B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 90.28B KRW | KR#1,858/2,421 Sec#149/231 |
| Net Assets | 7.21B KRW | KR#2,386/2,421 Sec#226/231 |
| Employees | 333 | KR#725/2,421 Sec#63/231 |
| Value | ||
| P/B | 2.96x | KR#2,104/2,421 Sec#165/231 |
| P/S | 0.44x | KR#828/2,421 Sec#32/231 |
| FCF Yield | -58.12% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROA | -18.93% | KR#2,235/2,421 Sec#173/231 |
| Op. Margin | -21.29% | KR#2,136/2,421 Sec#148/231 |
| Revenue Growth | 15.85% | KR#660/2,421 Sec#62/231 |
| Earnings Growth | -497.61% | KR#1,302/2,421 Sec#90/231 |
| Financial Health | ||
| Debt Ratio | 1152.42% | KR#2,369/2,421 Sec#227/231 |
| Total Debt | 50.05B KRW | KR#1,003/2,421 Sec#70/231 |
| FCF | -12.39B KRW | KR#1,769/2,421 Sec#157/231 |
| Cash | 1.57B KRW | KR#2,288/2,421 Sec#217/231 |
| Current Ratio | 0.38x | KR#2,193/2,421 Sec#213/231 |
| Performance | ||
| 1Y Return | -49.15% | KR#2,041/2,421 Sec#184/231 |
| 1M Return | -0.83% | KR#1,332/2,421 Sec#100/231 |
| From 52W High | -59.47% | KR#1,843/2,421 Sec#140/231 |
| 1Y MDD | -61.28% | KR#1,553/2,421 Sec#125/231 |
| Trading | ||
| Volume | 31,096 shares | KR#1,367/2,421 Sec#133/231 |
| Trading Value | 52.3M KRW | KR#1,822/2,421 Sec#188/231 |
| Foreign Own. | 1.27% | KR#1,928/2,421 Sec#187/231 |
| Per Share | ||
| EPS | -1,337 KRW | KR—/2,421 Sec—/231 |
| BPS | 564 KRW | KR#2,376/2,421 Sec#224/231 |
Company Info
Established in 2017 as a CRO providing non-clinical and clinical trial services across various fields, DT&CRO listed on KOSDAQ in 2022. The company conducts non-clinical tests like efficacy, pharmacokinetic, and GLP toxicology studies, as well as bioequivalence and clinical trials, and signed an FDA IND consulting MOU with a US research company in 2024. DT&CRO offers one-stop services from non-clinical to clinical and regulatory approval, emerging as a CRO industry leader through initiatives like AI-powered smart clinical trial platform development. DT&CRO is headquartered in Yongin-si, Gyeonggi-do.